MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
58.10
-1.10
-1.86%
Closed 19:49 03/11 EDT
OPEN
58.89
PREV CLOSE
59.20
HIGH
59.75
LOW
56.83
VOLUME
2.89M
TURNOVER
22.33M
52 WEEK HIGH
76.76
52 WEEK LOW
9.57
MARKET CAP
8.14B
P/E (TTM)
37.71
1D
5D
1M
3M
1Y
5Y
1D
Arrowhead (ARWR): Do Strong Q1 Results and Plozasiran Hopes Outweigh Insider Selling Signals?
Simply Wall St · 2d ago
Weekly Report: what happened at ARWR last week (0302-0306)?
Weekly Report · 3d ago
Weekly Report: what happened at ARWR last week (0223-0227)?
Weekly Report · 03/02 10:16
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation As Its RNAi Pipeline Advances To Phase 3 With Big Pharma Partners
Simply Wall St · 03/01 17:19
Arrowhead’s Expanded 2026 Conference Circuit and Phase 3 RNAi Pipeline Might Change The Case For Investing In Arrowhead Pharmaceuticals (ARWR)
Simply Wall St · 02/27 22:32
Why Is CRISPR Therapeutics Stock Surging Thursday?
Benzinga · 02/26 18:45
H.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
TipRanks · 02/26 15:55
GSK inks licensing deal worth up to $1B with China’s Frontier Bio
Seeking Alpha · 02/24 13:51
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.